PolyPid (NASDAQ:PYPD – Get Free Report) and InfuSystem (NYSE:INFU – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for PolyPid and InfuSystem, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PolyPid | 0 | 0 | 2 | 0 | 3.00 |
| InfuSystem | 0 | 0 | 0 | 2 | 4.00 |
PolyPid currently has a consensus target price of $10.50, suggesting a potential upside of 218.18%. InfuSystem has a consensus target price of $13.00, suggesting a potential upside of 62.91%. Given PolyPid’s higher possible upside, analysts clearly believe PolyPid is more favorable than InfuSystem.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PolyPid | N/A | N/A | -$23.86 million | ($7.81) | -0.42 |
| InfuSystem | $132.78 million | 1.28 | $870,000.00 | $0.06 | 133.00 |
InfuSystem has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
PolyPid has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Profitability
This table compares PolyPid and InfuSystem’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PolyPid | N/A | -1,219.71% | -134.48% |
| InfuSystem | 1.12% | 2.78% | 1.41% |
Institutional & Insider Ownership
26.5% of PolyPid shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 10.2% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
InfuSystem beats PolyPid on 11 of the 14 factors compared between the two stocks.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
About InfuSystem
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
